Printer Friendly

Proinflammatory Cytokine IL-17 Shows a Significant Association with Helicobacter pylori Infection and Disease Severity.

1. Introduction

Helicobacter pylori (H. pylori) infects and colonizes the gastric epithelium of humans, resulting in gastric disease of varying severity [1]. The immunopathogenesis of Helicobacter pylori infection is still an enigma. Host and bacterial factors play an important role in the immunopathogenesis [2-4]. The bacterium induces both innate and adaptive immune responses in local gastric environment as well as a heterogeneous systemic IgG response [5]. Many studies have described the development of H. pylori-induced gastritis as predominant, due to Th1 cells, while Th2 cells have a protective effect [6]. However, the Th1 response alone is insufficient to explain the pathogenesis of H. pylori-induced gastritis.

A role of Th17 cells in the pathogenesis of gastritis has been suggested by several groups [7]. Th17 cells are recently described to be important in immunity to extracellular bacterial and fungal infections [8]. The cytokine profile of Th17 cells includes IL-17A, IL-17F, IL-21, and IL-22. The expansion of the Th17 cells is promoted by IL-23 and IL-21 which is responsible for maintenance of the Th-17 cell population [9].

The immunopathogenic role of Th-17 cells has been described with regard to autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjogren syndrome, by promoting chronic inflammation [10, 11]. Further, Th17 cells have shown to be protective in colitis [12]. Studies done using H. pylori-infected biopsies report the upregulation of IL-17 at both RNA and protein levels compared to uninfected biopsies [13]. Further, the local IL-17 levels in the gastric mucosa at the infection site have been shown to have high IL-17 levels [14]. The cytokine IL-17 is suggested to play a decisive role in the neutrophil recruitment in H. pylori-infected gastric mucosa and stimulates the fibroblasts to produce matrix metalloproteinases which further contributes to mucosal damage. Recently, the reports on the association of Th17 cells with H. pylori infection have emerged but the exact role of Th17 cells in H. pylori infection is yet unclear.

2. Materials and Methods

Twenty H. pylori-positive patients (confirmed by histology) and 30 age sex-matched healthy control group were included in the study. Ethical approval was granted from the Ethics Review Committee, University of Sri Jayewardenepura (14/ 15) and Colombo South Teaching Hospital, Sri Lanka. The control group consisted of healthy individuals negative for H. pylori IgG (Bioactiva Diagnostica, GmBH), who did not have any symptoms of dyspepsia and were not under any health conditions requiring medical attention. Gastritis was staged according to the modified Sydney system in Hematoxylin & Eosin-stained biopsies. A blood specimen of 5 mL was collected from each patient and healthy individual for the ELISA procedure. The blood specimen was centrifuged, serum separated, and stored at -80[degrees]C.

2.1. Enzyme-Linked Immunosorbent Assay for Detection of Serum Cytokines and H. pylori IgG. The expression of selected cytokines (IL-10, IL-17, IL-21, IL-23, and TNF-[alpha]) in serum specimens were determined using enzyme-linked immunosorbent assay (Mabtech, Sweden). The healthy controls were selected using a H. pylori IgG assay (Bioactiva Diagnostica, GmBH). Healthy patients positive for H. pylori IgG were excluded from the study.

H. pylori IgG ELISA was carried out to determine the serological status of the healthy volunteers following the manufacturer's instructions (Bioactiva Diagnostica, GmBH). Briefly, precoated ELISA plates were incubated with serum specimens diluted according to the manufacturers' instructions. After incubating at 37[degrees]C for 1 hour, the plate was washed with washing buffer and conjugate solution was added. The plate was incubated at 20-25[degrees]C for 30 minutes before washing. The substrate solution was added to the plate and incubated at 20-25[degrees]C for 15 min.

For the determination of cytokines, the sterile 96-well plate was coated with coating antibody on the first day and incubated at 4-8[degrees]C overnight. The coated plate was washed with 200 [micro]L of PBS solution twice (pH 7.4). Incubation buffer (PBS + 0.05% Tween 20+1% BSA) 200 [micro]L was added to the wells (except blank) and allowed to incubate at room temperature. After 1 hour, the plate was washed with washing buffer five times.

Serial dilution of cytokine standards was prepared in the range instructed by the manufacturer and added to the wells (each standard was added to 2 wells to provide duplicates). The serum specimens were diluted 1: 1 with ELISA diluent and added to the wells in duplicate. The wells for blank control were left empty. The plate was allowed to incubate for 2 hours at room temperature. The plate was washed 5 times using wash buffer (PBS + 0.05% Tween 20).

The secondary antibody was added to the wells and the plate was incubated for 1 hour. The plate was washed 5 times and 100 [micro]L of streptavidin-HRP (diluted 1: 1000 in incubation buffer) was added to each well. After incubating for 1 hour, the plate was again washed 5 times. 100 [micro]L of TMB substrate was added to each well, and the plate was covered with aluminum foil and incubated at room temperature for 40 min. At the end of the incubation period, 100 [micro]L of stop solution (1 M [H.sub.2]S[O.sub.4] solution) was added to each well prior to absorbance measurement.

Absorbance of all ELISAs was measured at 450 nm using MPSCREEN MR-96A ELISA reader.

2.2. Data Analysis and Statistical Calculations. Corrected absorbance values (AbsC) were calculated by subtracting the mean absorbance value of blank sample (AbsB) from the mean absorbance value of the test sample (AbsT).

AbsC = AbsT - AbsB. (1)

Corrected absorbance values of all standards, patient samples, and healthy controls were calculated. Log 10 values of all unknown sample (test) concentrations were interpolated using a sigmoidal dose-response curve with GraphPad Prism version 7 (GraphPad Software Inc). Antilog values were calculated to determine the unknown sample concentration.

The cytokine expression values in patients and healthy controls were entered in a new data sheet in GraphPad Prism. The significance between H. pylori patients and healthy controls was calculated using Mann-Whitney U test using 95% confidence interval. The significant association of cytokine expression with disease severity was calculated using the Kruskal-Wallis test.

3. Results

The H. pylori-positive dyspeptic patient group consisted of 20 patients aged 18-70 years. Thirteen were male and 7 were female. The control group (H. pylori-negative, healthy) consisted of 18 males and 12 females with ages ranging from 20 to 65 years of age. Of the 20 H. pylori-infected patients, 13 had mild chronic gastritis while 6 had moderate gastritis and only 1 patient had severe gastritis.

Expression of serum cytokines (IL-17A, IL-21, IL-23, IL-10, and TNF-[alpha]) in H. pylori-infected patients was compared with healthy controls and correlated with disease severity (mild chronic gastritis, moderate chronic gastritis, and severe chronic gastritis).

On comparison, the association between H. pylori infection and cytokine expression levels, IL-17A (p <0.0001) and IL-23 (p = 0.0262) were significantly elevated in the patients with confirmed H. pylori infection (Figures 1(a) and 1(b)). Further, it was observed that IL-21 and TNF-[alpha] levels were elevated in this group although not statistically significant (Figures 1(c) and 1(d)). Table 1 depicts the mean and the range of cytokine concentrations for H. pylori-positive patients and healthy controls. The mean cytokine concentrations observed for IL-17A and IL-23 for H. pylori-positive group were 12.67 pg/mL and 7.06 pg/mL, respectively, while in healthy individuals, the mean concentrations were 8.37 pg/mL and 1.68 pg/mL, respectively.

Serum IL-17A concentration was statistically significant between healthy controls and patients with mild chronic gastritis (p = 0.0001) and with moderate to severe chronic gastritis (p = 0.0136). The expression of cytokines IL-23, IL-21, TNF-[alpha], and IL-10 did not have a significant association with the severity of chronic gastritis in this study (Figure 2, Table 2).

4. Discussion

The serum cytokine expressions of H. pylori-positive dyspeptic patients show a significant elevation of IL-17A and IL-23. Further, raised levels of IL-21 among H. pylori-positive patients suggest a possible role of Th17 cells in the immunopathogenesis of H. pylori-associated gastritis.

H. pylori infect the gastric mucosa, and hence, it can induce local as well as systemic immune response in the host. The mucosal cytokine expression in H. pylori infection has provided strong evidence for the inflammatory response mediated by H. pylori in the local mucosa [13, 15]. However, serum cytokine response to H. pylori infection needs elucidation as the infection can also produce systemic immune responses in the host [16-18]. In a study by Serelli-Lee et al., the circulating Th17 cells were elevated in patients with active H. pylori infection and significantly elevated in patients with past H. pylori infection compared to the healthy group. Their findings indicate elevation of Th17 cells in the gastric mucosa as well as in the blood indicating that serum cytokine levels can reflect the Th17 response in H. pylori infection [14]. Further, this is supported by studies reporting elevation of Th17-associated cytokines in the serum in H. pylori-infected patients [16]. In the present study, it was not possible to obtain mucosal biopsies from healthy individuals; therefore, the Th17-associated cytokine levels of serum was investigated.

Th17 cells are increasingly being associated with immunity to extracellular bacterial and fungal infections. Recent studies provide evidence for presence of Th17 cells in H. pylori-infected gastric biopsies and elevation of proinflammatory cytokines including IL-17 compared to healthy controls similar to our observations [7, 19]. Subsequently, Serelli-Lee et al. reported that Th17 cells persist even after H. pylori eradication resulting in persistence of an IL-17A response that may contribute to pathogenesis of gastric cancer from the early stages of H. pylori infection [14]. Serelli-Lee et al. hypothesized that chronic IL-17A signaling and coexpression of IL-22 may drive persistent expression of antimicrobial peptides and matrix metalloproteinases in the gastric mucosa promoting carcinogenesis.

IL-17A secretion by Th17 cell is regulated by IL-23 through a STAT3-dependent pathway [20]. IL-23 is secreted by several immune cells including dendritic cells, macrophages, and neutrophils in the gastric mucosa. Elevated IL-23 levels in the H. pylori-infected gastric biopsies have been reported by Koussoulas in 2008 [21]. Horvath et al. reported a positive correlation between levels of IL-23 and the infiltration levels of neutrophils and monocytes in patients with H. pylori infection [22]. It is suggested that IL-23 plays a role in the activation of the immune response and induction of gastritis in response to H. pylori.

The expression levels of TNF-[alpha] was relatively high in all H. pylori-positive patients, and a high expression of TNF-[alpha] was observed in patients with mild chronic gastritis and moderate to severe chronic gastritis compared to controls, even if there was no significant difference. IL-17 can stimulate TNF-[alpha] secretion along with induction of other proinflammatory cytokines IL-1, IL-6, and matrix metalloproteinases from both immune and nonimmune cells [23]. The elevation of TNF-[alpha] seen in our study can be explained by the significantly elevated IL-17 seen in H. pylori-positive patients compared with the healthy controls. TNF-[alpha] is a proinflammatory cytokine which can act on endothelial cells to stimulate expression of adhesion molecules facilitating the extravasation of neutrophils into the site of infection on the mucosal tissue. It can further activate T cells and stimulate cytokine production by macrophages and monocytes [23]. TNF-[alpha] has been shown to be associated with increased apoptosis independently of the VacA and CagA status of H. pylori. Siregar et al. [18] reported that TNF-a expression was significantly associated with both H. pylori infection and degree of chronic inflammation [18]. Although not significant, a clear elevation in the mean cytokine expression was observed in moderate to severe gastritis patients compared to mild gastritis patients in our study which further supports the findings of Siregar et al.

In a study conducted in Iran, mucosal IL-21 mRNA levels were quantitatively analyzed using real-time PCR. IL-21 expression was significantly higher in H. pylori-infected patients and a significant correlation was observed between IL-21 mRNA levels and chronic inflammation [24]. In our study, the expression of IL-21 was higher in H. pylori-infected patients but no significant association could be observed. The elevation of IL-21 among H. pylori-infected patients observed in our study and the significant elevation of IL-17 together suggests that in the Th-17 pathway, IL-21 helps to maintain the Th-17 cells and thus regulate Th17 effector responses during chronic H. pylori infection.

5. Conclusions

In conclusion, the significant elevation of IL-17 and IL-23 and high expression of IL-21 and TNF-[alpha] in the serum of H. pylori-positive patients further supports the role of Th-17 cells in the pathogenesis of H. pylori infection and the severity of gastritis.

Conflicts of Interest

The authors declare that there are no conflicts of interest and no financial conflicts regarding the publication of this paper.


This study was assisted by the staff at the Endoscopy Unit of the Colombo South Teaching Hospital, the staff at the Departments of Pathology and Microbiology, Faculty of Medical Sciences, University of Sri Jayewardenepura. This study was supported by the National Science Foundation Research Scholarship (NSF/SCH/2015/04) and the University of Sri Jayewardenepura Research Grant (ASP/01/RE/MED/ 2017/28).


[1] T. U. Westblom, S. J. Czinn, and J. G. Nedrud, Gastroduodenal Disease and Helicobacter pylori: Pathophysiology, Diagnosis and Treatment, Springer, Berlin, 1999.

[2] M. J. Blaser, G. I. Perez-perez, H. Kleanthous et al., "Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach," Cancer Research, vol. 55, no. 10, pp. 2111-2115, 1995.

[3] M. Chen, C. He, X. Meng, and Y. Yuan, "Association of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancer," World Journal of Gastroenterology, vol. 19, no. 26, pp. 4242-4251, 2013.

[4] C. Zambon, D. Basso, F. Navaglia et al., "Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome," Cytokine, vol. 29, no. 4, pp. 141-152, 2005.

[5] N. Bhat, J. Gaensbauer, R. M. Peek et al., "Local and systemic immune and inflammatory responses to Helicobacter pylori strains," Clinical and Vaccine Immunology, vol. 12, pp. 1393-1400, 2005.

[6] L. E. Smythies, K. B. Waites, J. R. Lindsey, P. R. Harris, P. Ghiara, and P. D. Smith, "Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-[gamma], gene-deficient mice," The Journal of Immunology, vol. 165, no. 2, pp. 1022-1029, 2000.

[7] J. H. Gil, J. W. Seo, M.-S. Cho, J.-H. Ahn, and H. Y. Sung, "Role of Treg and TH17 cells of the gastric mucosa in children with Helicobacter pylori gastritis," Journal of Pediatric Gastroenterology and Nutrition, vol. 58, no. 2, pp. 245-251, 2014.

[8] M. M. Curtis and S. S. Way, "Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens," Immunology, vol. 126, pp. 177-185, 2008.

[9] S. C. Liang, X.-Y. Tan, D. P. Luxenberg et al., "Interleukin (IL)22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides," The Journal of Experimental Medicine, vol. 203, no. 10, pp. 2271-2279, 2006.

[10] J. C. Crispin, M. Oukka, G. Bayliss et al., "Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys," The Journal of Immunology, vol. 181, no. 12, pp. 8761-8766, 2008.

[11] G. E. Katsifis, S. Rekka, N. M. Moutsopoulos, S. Pillemer, and S. M. Wahl, "Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis," The American Journal of Pathology, vol. 175, no. 3, pp. 1167-1177, 2009.

[12] W. O'Connor Jr., M. Kamanaka, C. J. Booth et al., "A protective function for interleukin 17A in T cell-mediated intestinal inflammation," Nature Immunology, vol. 10, no. 6, pp. 603-609, 2009.

[13] F. Luzza, T. Parrello, G. Monteleone et al., "Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa," Journal of Immunology, vol. 165, no. 9, pp. 5332-5337, 2000.

[14] V. Serelli-Lee, L. Ling, C. Ho et al., "Persistent Helicobacter pylori specific Th17 responses in patients with past H. pylori infection are associated with elevated gastric mucosal IL-1[beta]," PLoS One, vol. 7, pp. 1-11, 2012.

[15] H. Abdollahi, S. Shams, M. J. Zahedi, S. Darvish Moghadam, M. M. Hayatbakhsh, and A. Jafarzadeh, "IL-10, TNF-[alpha] and IFN-y levels in serum and stomach mucosa of Helicobacter pylori-infected patients," Iranian Journal of Allergy, Asthma and Immunology, vol. 10, pp. 267-271, 2011.

[16] S. A. Shamsdin, A. Alborzi, M. Rasouli, and M. K. Hosseini, "Alterations in Th17 and the respective cytokine levels in Helicobacter pylori-induced stomach diseases," Helicobacter, vol. 20, no. 6, pp. 460-475, 2015.

[17] G. Siregar, S. Halim, and R. Sitepu, "Serum IL-10, MMP-7, MMP-9 levels in Helicobacter pylori infection and correlation with degree of gastritis," Open Access Macedonian Journal of Medical Sciences, vol. 4, pp. 359-363, 2016.

[18] G. A. Siregar, S. Halim, and R. R. Sitepu, "Serum TNF-[alpha], IL-8, VEGF levels in Helicobacter pylori infection and their association with degree of gastritis," Indonesian Journal of Internal Medicine, vol. 47, pp. 120-126, 2014.

[19] T. Mizuno, T. Ando, K. Nobata et al., "Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization," World Journal of Gastroenterology, vol. 11, no. 40, pp. 6305-6311, 2005.

[20] S. Aggarwal, N. Ghilardi, M.-H. Xie, F. J. De Sauvage, and A. L. Gurney, "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17," The Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910-1914, 2002.

[21] V. Koussoulas, S. Vassiliou, E. J. Giamarellos-Bourboulis et al., "Implications for a role of interleukin-23 in the pathogenesis of chronic gastritis and of peptic ulcer disease," Clinical & Experimental Immunology, vol. 156, no. 1, pp. 97-101, 2008.

[22] D. J. Horvath Jr., M. Kay Washington, V. A. Cope, H. M. S. Algood, T. Blanchard, and D. Bimczok, "IL-23 contributes to control of chronic Helicobacter pylori infection and the development of T helper responses in a mouse model," Frontiers in Immunology, vol. 3, pp. 1-9, 2012.

[23] D. V. Jovanovic, J. A. Di Battista, J. Martel-Pelletier et al., "IL-17 stimulates the production and expression of proinflammatory cytokines, IL-[beta], and TNF-[alpha], by human macrophages," Journal of Immunology, vol. 160, pp. 3513-3521, 1998.

[24] N. Bagheri, F. Azadegan-dehkordi, M. Shirzad et al., "Mucosal interleukin-21 mRNA expression level is high in patients with Helicobacter pylori and is associated with the severity of gastritis," Central European Journal of Immunology, vol. 40, no. 1, pp. 61-67, 2015.

Piyumali Sandareka Arachchi, (1) Neluka Fernando, (1) Manjula Manoji Weerasekera, (1) Bimalka Senevirathna, (2) Deepaka D. Weerasekera, (3) and Chinthika Prabhashinie Gunasekara (1)

(1) Department of Microbiology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka

(2) Department of Pathology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka

(3) Department of Surgery, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka

Correspondence should be addressed to Chinthika Prabhashinie Gunasekara;

Received 3 July 2017; Revised 11 October 2017; Accepted 29 October 2017; Published 17 December 2017

Academic Editor: Spiros D. Ladas

Caption: Figure 1: Comparison of IL-17, IL-23, IL-21, TNF-[alpha], and IL-10 levels (pg/mL) of H. pylori-infected patients and healthy individuals. Expression levels of selected cytokines were compared between H. pylori- infected patients (n = 20) and healthy controls (n = 30). Association of cytokine expression with H. pylori infection was calculated using the Mann-Whitney U test. (a) Comparison of IL-17 concentration among the two groups (p < 0.0001). (b) Comparison of IL-23 expression among the two groups (p = 0.0262). (c) Comparison of IL-21 expression (p = 0.6473). (d) TNF-[alpha] expression levels among H. pylori-infected patients and healthy controls (p = 0.4414). (e) Comparison of IL-10 concentration among the two groups (p = 0.4482).

Caption: Figure 2: Correlation of cytokine expression in H. pylori-infected patients with disease severity. The expression of cytokines in healthy individuals, H. pylori-infected patients with mild chronic gastritis (CG), and H. pylori-infected patients with moderate to severe chronic gastritis was compared using the Kruskal-Wallis test. (a) Comparison of IL-17 expression (p < 0.0001). (b) Comparison of IL-23 expression (p = 0.1262). (c) Comparison of IL-21 expression (p = 0.6077). (d) Comparison of TNF-[alpha] expression (p = 0.6833). (e) Comparison of IL-10 expression (p = 0.5558).
Table 1: Expression of cytokines in serum and their association with
H. pylori infection.

Cytokine                 Healthy group

                       Range          Mean

IL-10                1.77-31.13        8.83
IL-17                3.20-11.86        8.37
IL-21            Undetectable-14.8     4.86
IL-23            Undetectable-11.8     1.68
TNF-[alpha]      Undetectable-984.7   224.6

Cytokine          H. pylori-infected group     p value

                       Range          Mean

IL-10                 0-19.04          6.91     0.4482
IL-17                8.24-16.74       12.67    <0.0001 *
IL-21            Undetectable-37.62    7.89     0.6473
IL-23            Undetectable-38.08    7.06     0.0262 *
TNF-[alpha]      Undetectable-984.7   276.4     0.4414

* p < 0.05.

Table 2: Expression of cytokines in serum and their association
with disease severity.

Participant group depending      Mean expression (pg/mL)
on disease severity

                                 IL-10   IL-17       IL-21

Healthy controls                 8.825   8.367       4.861
H. pylon-infected patients       6.579   14.52       9.518
  with mild chronic gastritis
H. pylori-infected patients      12.82   12.0        21.86
  with moderate to severe
chronic gastritis
p value                          0.5558  <0.0001 *   0.6077

Participant group depending      Mean expression (pg/mL)
on disease severity

                                 IL-23    TNF-[alpha]

Healthy controls                 26.52    224.6
H. pylon-infected patients       16.43    241.6
  with mild chronic gastritis
H. pylori-infected patients      29.61    341.2
  with moderate to severe
chronic gastritis
p value                          0.1262   0.6833

* < 0.05.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Arachchi, Piyumali Sandareka; Fernando, Neluka; Weerasekera, Manjula Manoji; Senevirathna, Bimalka;
Publication:Gastroenterology Research and Practice
Date:Jan 1, 2018
Previous Article:Mechanisms and Management of Acute Pancreatitis.
Next Article:High Visceral to Subcutaneous Fat Ratio Is Associated with Increased Postoperative Inflammatory Response after Colorectal Resection in Inflammatory...

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters